Crea, Francesco
(2019).
|
(Accepted Manuscript)
Due to publisher licensing restrictions, this file is not available for public download until 19 September 2020 Click here to request a copy from the OU Author. |
| DOI (Digital Object Identifier) Link: | https://doi.org/10.2217/epi-2019-0236 |
|---|---|
| Google Scholar: | Look up in Google Scholar |
Abstract
Francesco Crea speaks to Lucy Chard, Commissioning Editor. Dr Crea’s lab studies the role of epigenetic factors and noncoding RNA in cancer initiation and progression. While working at the National Cancer Institute (USA), Dr Crea has demonstrated that polycomb-targeting drugs eradicate prostate cancer stem cells. While working at the BC Cancer Agency (Canada), Dr Crea discovered and patented PCAT18, a long noncoding RNA involved in prostate cancer metastasis. Dr Crea has received awards from the American Society of Clinical Oncology, from the Prostate Cancer Program and from Prostate Cancer Foundation BC. He is also an Editorial Board member for Epigenomics. His team is currently working on developing new biomarkers and therapeutic targets for incurable prostate and breast cancers.
| Item Type: | Journal Item |
|---|---|
| Copyright Holders: | 2019 Future Medicine Ltd |
| ISSN: | 1750-192X |
| Extra Information: | Interview |
| Keywords: | Interview; cancer therapeutics; epigenomics; lncRNA; metastasis; neuroendocrine prostate cancer; patient outcomes |
| Academic Unit/School: | Faculty of Science, Technology, Engineering and Mathematics (STEM) > Life, Health and Chemical Sciences Faculty of Science, Technology, Engineering and Mathematics (STEM) |
| Item ID: | 66817 |
| SWORD Depositor: | Jisc Publications-Router |
| Depositing User: | Jisc Publications-Router |
| Date Deposited: | 20 Sep 2019 08:24 |
| Last Modified: | 10 Nov 2019 00:49 |
| URI: | http://oro.open.ac.uk/id/eprint/66817 |
| Share this page: |     |
Metrics
Altmetrics from Altmetric | Citations from Dimensions |
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)